These agents demonstrated a limited OS benefit, with substantial off-target side effects due to their nonselective nature, and were primarily used as off-label agents in RET-fusion-positive NSCLC [155,156,157,158]. The gene discussed is RET; the disease is non-small cell lung carcinoma.